IL140078A - Benzothiepine-1,1-dioxide derivatives, method for producing them, medicaments containing these compounds and their use - Google Patents

Benzothiepine-1,1-dioxide derivatives, method for producing them, medicaments containing these compounds and their use

Info

Publication number: IL140078A
Authority: IL; Israel
Prior art keywords: radical; compound; formula; alkyl; compounds
Prior art date: 1998-06-10

Application number

IL14007899A

Other languages

English (en)

Other versions

IL140078A0 (en

Original Assignee

Aventis Pharma Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-06-10

Filing date

1999-05-29

Publication date

2004-08-31

1999-05-29 Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh

2002-02-10 Publication of IL140078A0 publication Critical patent/IL140078A0/xx

2004-08-31 Publication of IL140078A publication Critical patent/IL140078A/en

Links

150000001875 compounds Chemical class 0.000 title claims abstract description 78
239000003814 drug Substances 0.000 title claims description 10
238000004519 manufacturing process Methods 0.000 title claims 6
LSXZSLZITPNDSA-UHFFFAOYSA-N 1$l^{6}-benzothiepine 1,1-dioxide Chemical class O=S1(=O)C=CC=CC2=CC=CC=C12 LSXZSLZITPNDSA-UHFFFAOYSA-N 0.000 title description 5
235000000346 sugar Nutrition 0.000 claims abstract description 30
150000003839 salts Chemical class 0.000 claims abstract description 22
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims abstract description 17
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims abstract description 17
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 17
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims abstract description 15
125000006239 protecting group Chemical group 0.000 claims abstract description 9
239000000203 mixture Substances 0.000 claims description 20
238000011282 treatment Methods 0.000 claims description 11
238000000034 method Methods 0.000 claims description 10
238000002360 preparation method Methods 0.000 claims description 9
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
239000000546 pharmaceutical excipient Substances 0.000 claims description 6
230000008569 process Effects 0.000 claims description 6
238000011321 prophylaxis Methods 0.000 claims description 4
208000031226 Hyperlipidaemia Diseases 0.000 claims description 3
150000001412 amines Chemical class 0.000 claims description 3
201000001883 cholelithiasis Diseases 0.000 claims description 3
208000001130 gallstones Diseases 0.000 claims description 3
238000002156 mixing Methods 0.000 claims description 3
229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims description 2
208000017170 Lipid metabolism disease Diseases 0.000 claims description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 2
230000008030 elimination Effects 0.000 claims description 2
238000003379 elimination reaction Methods 0.000 claims description 2
239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims description 2
230000002265 prevention Effects 0.000 claims description 2
208000024891 symptom Diseases 0.000 claims description 2
125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
150000003254 radicals Chemical class 0.000 description 25
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 19
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 14
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 10
230000029142 excretion Effects 0.000 description 9
229910021529 ammonia Inorganic materials 0.000 description 7
-1 for example Chemical class 0.000 description 7
IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 6
230000002550 fecal effect Effects 0.000 description 6
239000003826 tablet Substances 0.000 description 6
230000015572 biosynthetic process Effects 0.000 description 5
230000000694 effects Effects 0.000 description 5
239000007787 solid Substances 0.000 description 5
239000000243 solution Substances 0.000 description 5
238000003786 synthesis reaction Methods 0.000 description 5
238000012360 testing method Methods 0.000 description 5
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
241001465754 Metazoa Species 0.000 description 4
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
239000003613 bile acid Substances 0.000 description 4
239000000470 constituent Substances 0.000 description 4
238000003818 flash chromatography Methods 0.000 description 4
238000009472 formulation Methods 0.000 description 4
239000007788 liquid Substances 0.000 description 4
239000008194 pharmaceutical composition Substances 0.000 description 4
239000000725 suspension Substances 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
239000002253 acid Substances 0.000 description 3
230000009471 action Effects 0.000 description 3
239000007864 aqueous solution Substances 0.000 description 3
239000008187 granular material Substances 0.000 description 3
229910052943 magnesium sulfate Inorganic materials 0.000 description 3
238000005259 measurement Methods 0.000 description 3
239000012074 organic phase Substances 0.000 description 3
239000000843 powder Substances 0.000 description 3
239000000651 prodrug Substances 0.000 description 3
229940002612 prodrug Drugs 0.000 description 3
HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 2
KBVULDQKXUWUNV-UHFFFAOYSA-N 2,3,4,5,6-pentaacetyloxyhexanoic acid Chemical compound CC(=O)OCC(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(O)=O KBVULDQKXUWUNV-UHFFFAOYSA-N 0.000 description 2
RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
229920000084 Gum arabic Polymers 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
241000700159 Rattus Species 0.000 description 2
241000978776 Senegalia senegal Species 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
WBWWGRHZICKQGZ-UHFFFAOYSA-N Taurocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCCS(O)(=O)=O)C)C1(C)C(O)C2 WBWWGRHZICKQGZ-UHFFFAOYSA-N 0.000 description 2
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
FPQVGDGSRVMNMR-JCTPKUEWSA-N [[(z)-(1-cyano-2-ethoxy-2-oxoethylidene)amino]oxy-(dimethylamino)methylidene]-dimethylazanium;tetrafluoroborate Chemical compound F[B-](F)(F)F.CCOC(=O)C(\C#N)=N/OC(N(C)C)=[N+](C)C FPQVGDGSRVMNMR-JCTPKUEWSA-N 0.000 description 2
239000000205 acacia gum Substances 0.000 description 2
235000010489 acacia gum Nutrition 0.000 description 2
150000001450 anions Chemical class 0.000 description 2
239000002585 base Substances 0.000 description 2
MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 2
239000002775 capsule Substances 0.000 description 2
238000002485 combustion reaction Methods 0.000 description 2
230000001186 cumulative effect Effects 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
231100000673 dose–response relationship Toxicity 0.000 description 2
125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
238000005567 liquid scintillation counting Methods 0.000 description 2
239000007937 lozenge Substances 0.000 description 2
235000019341 magnesium sulphate Nutrition 0.000 description 2
150000002923 oximes Chemical class 0.000 description 2
238000007493 shaping process Methods 0.000 description 2
239000000126 substance Substances 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
150000008163 sugars Chemical class 0.000 description 2
WBWWGRHZICKQGZ-HZAMXZRMSA-N taurocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@@H](O)C1 WBWWGRHZICKQGZ-HZAMXZRMSA-N 0.000 description 2
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
HFVMEOPYDLEHBR-UHFFFAOYSA-N (2-fluorophenyl)-phenylmethanol Chemical compound C=1C=CC=C(F)C=1C(O)C1=CC=CC=C1 HFVMEOPYDLEHBR-UHFFFAOYSA-N 0.000 description 1
ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 description 1
QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 description 1
JVKUCNQGESRUCL-UHFFFAOYSA-N 2-Hydroxyethyl 12-hydroxyoctadecanoate Chemical compound CCCCCCC(O)CCCCCCCCCCC(=O)OCCO JVKUCNQGESRUCL-UHFFFAOYSA-N 0.000 description 1
MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 1
MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
KQIGMPWTAHJUMN-UHFFFAOYSA-N 3-aminopropane-1,2-diol Chemical compound NCC(O)CO KQIGMPWTAHJUMN-UHFFFAOYSA-N 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
UOQHWNPVNXSDDO-UHFFFAOYSA-N 3-bromoimidazo[1,2-a]pyridine-6-carbonitrile Chemical compound C1=CC(C#N)=CN2C(Br)=CN=C21 UOQHWNPVNXSDDO-UHFFFAOYSA-N 0.000 description 1
BWGRDBSNKQABCB-UHFFFAOYSA-N 4,4-difluoro-N-[3-[3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-thiophen-2-ylpropyl]cyclohexane-1-carboxamide Chemical compound CC(C)C1=NN=C(C)N1C1CC2CCC(C1)N2CCC(NC(=O)C1CCC(F)(F)CC1)C1=CC=CS1 BWGRDBSNKQABCB-UHFFFAOYSA-N 0.000 description 1
HVCNXQOWACZAFN-UHFFFAOYSA-N 4-ethylmorpholine Chemical compound CCN1CCOCC1 HVCNXQOWACZAFN-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
206010003210 Arteriosclerosis Diseases 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
OJRUSAPKCPIVBY-KQYNXXCUSA-N C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N Chemical compound C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N OJRUSAPKCPIVBY-KQYNXXCUSA-N 0.000 description 1
229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 description 1
YTBSYETUWUMLBZ-UHFFFAOYSA-N D-Erythrose Natural products OCC(O)C(O)C=O YTBSYETUWUMLBZ-UHFFFAOYSA-N 0.000 description 1
YTBSYETUWUMLBZ-IUYQGCFVSA-N D-erythrose Chemical compound OC[C@@H](O)[C@@H](O)C=O YTBSYETUWUMLBZ-IUYQGCFVSA-N 0.000 description 1
RGHNJXZEOKUKBD-MGCNEYSASA-N D-galactonic acid Chemical compound OC[C@@H](O)[C@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-MGCNEYSASA-N 0.000 description 1
DSLZVSRJTYRBFB-LLEIAEIESA-N D-glucaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 description 1
RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
MNQZXJOMYWMBOU-VKHMYHEASA-N D-glyceraldehyde Chemical compound OC[C@@H](O)C=O MNQZXJOMYWMBOU-VKHMYHEASA-N 0.000 description 1
HAIWUXASLYEWLM-UHFFFAOYSA-N D-manno-Heptulose Natural products OCC1OC(O)(CO)C(O)C(O)C1O HAIWUXASLYEWLM-UHFFFAOYSA-N 0.000 description 1
RGHNJXZEOKUKBD-MBMOQRBOSA-N D-mannonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O RGHNJXZEOKUKBD-MBMOQRBOSA-N 0.000 description 1
HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
206010056474 Erythrosis Diseases 0.000 description 1
229930091371 Fructose Natural products 0.000 description 1
239000005715 Fructose Substances 0.000 description 1
RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
DSLZVSRJTYRBFB-UHFFFAOYSA-N Galactaric acid Natural products OC(=O)C(O)C(O)C(O)C(O)C(O)=O DSLZVSRJTYRBFB-UHFFFAOYSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
SHBUUTHKGIVMJT-UHFFFAOYSA-N Hydroxystearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OO SHBUUTHKGIVMJT-UHFFFAOYSA-N 0.000 description 1
208000035150 Hypercholesterolemia Diseases 0.000 description 1
206010021024 Hypolipidaemia Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
208000007976 Ketosis Diseases 0.000 description 1
HSNZZMHEPUFJNZ-UHFFFAOYSA-N L-galacto-2-Heptulose Natural products OCC(O)C(O)C(O)C(O)C(=O)CO HSNZZMHEPUFJNZ-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
UEZVMMHDMIWARA-UHFFFAOYSA-N Metaphosphoric acid Chemical compound OP(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-N 0.000 description 1
CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
229920000715 Mucilage Polymers 0.000 description 1
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
241000700157 Rattus norvegicus Species 0.000 description 1
PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
HAIWUXASLYEWLM-AZEWMMITSA-N Sedoheptulose Natural products OC[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@](O)(CO)O1 HAIWUXASLYEWLM-AZEWMMITSA-N 0.000 description 1
229920001304 Solutol HS 15 Polymers 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical compound [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
GAMPNQJDUFQVQO-UHFFFAOYSA-N acetic acid;phthalic acid Chemical compound CC(O)=O.OC(=O)C1=CC=CC=C1C(O)=O GAMPNQJDUFQVQO-UHFFFAOYSA-N 0.000 description 1
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
239000013543 active substance Substances 0.000 description 1
239000000853 adhesive Substances 0.000 description 1
IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 1
IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
150000001323 aldoses Chemical class 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
150000001447 alkali salts Chemical class 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
150000003863 ammonium salts Chemical class 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
229920006318 anionic polymer Polymers 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
208000011775 arteriosclerosis disease Diseases 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
159000000007 calcium salts Chemical class 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
229940081734 cellulose acetate phthalate Drugs 0.000 description 1
229960005110 cerivastatin Drugs 0.000 description 1
SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
125000001309 chloro group Chemical class Cl* 0.000 description 1
239000012230 colorless oil Substances 0.000 description 1
229940126543 compound 14 Drugs 0.000 description 1
229940125758 compound 15 Drugs 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
239000002702 enteric coating Substances 0.000 description 1
238000009505 enteric coating Methods 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
LCFXLZAXGXOXAP-UHFFFAOYSA-N ethyl 2-cyano-2-hydroxyiminoacetate Chemical compound CCOC(=O)C(=NO)C#N LCFXLZAXGXOXAP-UHFFFAOYSA-N 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
210000003608 fece Anatomy 0.000 description 1
229960003765 fluvastatin Drugs 0.000 description 1
DSLZVSRJTYRBFB-DUHBMQHGSA-N galactaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O DSLZVSRJTYRBFB-DUHBMQHGSA-N 0.000 description 1
229930182830 galactose Natural products 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000000174 gluconic acid Substances 0.000 description 1
229950006191 gluconic acid Drugs 0.000 description 1
235000012208 gluconic acid Nutrition 0.000 description 1
229960002442 glucosamine Drugs 0.000 description 1
239000008103 glucose Substances 0.000 description 1
229940097043 glucuronic acid Drugs 0.000 description 1
150000002337 glycosamines Chemical class 0.000 description 1
230000036541 health Effects 0.000 description 1
125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
229940072106 hydroxystearate Drugs 0.000 description 1
210000003405 ileum Anatomy 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
239000003701 inert diluent Substances 0.000 description 1
239000000543 intermediate Substances 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
125000000654 isopropylidene group Chemical group C(C)(C)=* 0.000 description 1
150000002584 ketoses Chemical class 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 1
239000008101 lactose Substances 0.000 description 1
229960004844 lovastatin Drugs 0.000 description 1
PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
239000001630 malic acid Substances 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N methanesulfonic acid Substances CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
239000007764 o/w emulsion Substances 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
235000010603 pastilles Nutrition 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
229940057847 polyethylene glycol 600 Drugs 0.000 description 1
159000000001 potassium salts Chemical class 0.000 description 1
229960002965 pravastatin Drugs 0.000 description 1
TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 1
238000003825 pressing Methods 0.000 description 1
238000000746 purification Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
239000013558 reference substance Substances 0.000 description 1
230000033764 rhythmic process Effects 0.000 description 1
HSNZZMHEPUFJNZ-SHUUEZRQSA-N sedoheptulose Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO HSNZZMHEPUFJNZ-SHUUEZRQSA-N 0.000 description 1
238000000926 separation method Methods 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000012439 solid excipient Substances 0.000 description 1
239000012453 solvate Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000007858 starting material Substances 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
239000001384 succinic acid Substances 0.000 description 1
150000005846 sugar alcohols Chemical class 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
150000004044 tetrasaccharides Chemical class 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
150000004043 trisaccharides Chemical class 0.000 description 1
125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
239000007762 w/o emulsion Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D337/00—Heterocyclic compounds containing rings of more than six members having one sulfur atom as the only ring hetero atom
- C07D337/02—Seven-membered rings
- C07D337/06—Seven-membered rings condensed with carbocyclic rings or ring systems
- C07D337/08—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/04—Drugs for disorders of the urinary system for urolithiasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06086—Dipeptides with the first amino acid being basic
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Polymers & Plastics (AREA)
Obesity (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Gastroenterology & Hepatology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Peptides Or Proteins (AREA)
Saccharide Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

IL14007899A 1998-06-10 1999-05-29 Benzothiepine-1,1-dioxide derivatives, method for producing them, medicaments containing these compounds and their use IL140078A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE19825804A DE19825804C2 (de)	1998-06-10	1998-06-10	1,4-Benzothiepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
PCT/EP1999/003743 WO1999064409A2 (de)	1998-06-10	1999-05-29	Benzothiepin-1,1-dioxidderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung

Publications (2)

Publication Number	Publication Date
IL140078A0 IL140078A0 (en)	2002-02-10
IL140078A true IL140078A (en)	2004-08-31

Family

ID=7870440

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL14007899A IL140078A (en)	1998-06-10	1999-05-29	Benzothiepine-1,1-dioxide derivatives, method for producing them, medicaments containing these compounds and their use

Country Status (25)

Country	Link
US (1)	US6387944B1 (pl)
EP (2)	EP1086092B1 (pl)
JP (2)	JP4374426B2 (pl)
KR (2)	KR100681721B1 (pl)
CN (2)	CN1127497C (pl)
AR (2)	AR018633A1 (pl)
AT (2)	ATE227715T1 (pl)
AU (2)	AU753275B2 (pl)
BR (2)	BR9912188B1 (pl)
CA (2)	CA2334775C (pl)
CZ (2)	CZ297989B6 (pl)
DE (3)	DE19825804C2 (pl)
DK (2)	DK1086092T3 (pl)
ES (2)	ES2182535T3 (pl)
HU (2)	HU229761B1 (pl)
ID (2)	ID28695A (pl)
IL (1)	IL140078A (pl)
NO (1)	NO327075B1 (pl)
NZ (1)	NZ508681A (pl)
PL (2)	PL196074B1 (pl)
PT (2)	PT1086092E (pl)
RU (2)	RU2215001C2 (pl)
TR (2)	TR200003634T2 (pl)
WO (2)	WO1999064410A1 (pl)
ZA (2)	ZA200007061B (pl)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6642268B2 (en)	1994-09-13	2003-11-04	G.D. Searle & Co.	Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
US6221897B1 (en) *	1998-06-10	2001-04-24	Aventis Pharma Deutschland Gmbh	Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
DK1140184T3 (da)	1998-12-23	2003-09-29	Searle Llc	Kombinationer af cholesterylestertransferproteinhæmmere og nikotinsyrederivater til hjertekar indikationer
SE0000772D0 (sv)	2000-03-08	2000-03-08	Astrazeneca Ab	Chemical compounds
HUP0401081A3 (en) *	2000-12-21	2010-06-28	Sanofi Aventis Deutschland	Novel 1,2-diphenzylazetidinones, method for producing the same, medicaments containing said compounds, and their use
EG26979A (en)	2000-12-21	2015-03-01	Astrazeneca Ab	Chemical compounds
DE10064402A1 (de) *	2000-12-21	2002-06-27	Aventis Pharma Gmbh	Diphenylazetidinonderivate, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
BR0212031A (pt) *	2001-08-22	2004-08-03	Aventis Pharma Gmbh	Preparados de combinação de derivados de 1,1-dióxido de 1-4-benzotiepina com outras substâncias ativas e seu emprego
GB0121337D0 (en)	2001-09-04	2001-10-24	Astrazeneca Ab	Chemical compounds
GB0121621D0 (en)	2001-09-07	2001-10-31	Astrazeneca Ab	Chemical compounds
GB0121622D0 (en)	2001-09-07	2001-10-31	Astrazeneca Ab	Chemical compounds
PL216023B1 (pl)	2001-09-08	2014-02-28	Astrazeneca Ab	Pochodna benzotiadiazepiny, kompozycja farmaceutyczna zawierajaca pochodna benzotiadiazepiny oraz zastosowania pochodnej benzotiadiazepiny
AU2003207431A1 (en)	2002-01-17	2003-09-02	Pharmacia Corporation	Novel alkyl/aryl hydroxy or keto thiepines.
GB0209467D0 (en)	2002-04-25	2002-06-05	Astrazeneca Ab	Chemical compounds
GB0213669D0 (en)	2002-06-14	2002-07-24	Astrazeneca Ab	Chemical compounds
SE0201937D0 (sv)	2002-06-20	2002-06-20	Astrazeneca Ab	Therapeutic agents
FR2848452B1 (fr) *	2002-12-12	2007-04-06	Aventis Pharma Sa	Application des inhibiteurs de recapture intestinale des acides biliaires pour la prevention et le traitement de la maladie d'alzheimer
US20040138145A1 (en) *	2002-12-12	2004-07-15	Aventis Pharma S.A.	Application of intestinal biliary acid reuptake inhibitors for the prevention and treatment of alzheimer's disease
GB0304194D0 (en)	2003-02-25	2003-03-26	Astrazeneca Ab	Chemical compounds
GB0307918D0 (en)	2003-04-05	2003-05-14	Astrazeneca Ab	Therapeutic use
DE102006053635B4 (de) *	2006-11-14	2011-06-30	Sanofi-Aventis Deutschland GmbH, 65929	Neue mit Benzylresten substituierte 1,4-Benzothiepin-1,1-Dioxidderivate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
DE102006053636B4 (de) *	2006-11-14	2008-09-18	Sanofi-Aventis Deutschland Gmbh	Neue mit Cyclohexylresten substituierte 1,4-Benzothiepin-1,1-Dioxidderivate und deren Verwendung
US20100221513A1 (en) *	2008-09-05	2010-09-02	Wisconsin Alumni Research Foundation	Self sintering transparent nanoporous thin-films for use in self-cleaning, anti-fogging, anti-corrosion, anti-erosion electronic and optical applications
EP3593802A3 (en)	2010-05-26	2020-03-25	Satiogen Pharmaceuticals, Inc.	Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
ES2586931T3 (es)	2010-11-04	2016-10-19	Albireo Ab	Inhibidores de IBAT para el tratamiento de enfermedades hepáticas
RU2619215C2 (ru)	2010-11-08	2017-05-12	Альбирео Аб	Фармацевтическая комбинация, включающая ibat-ингибитор и связующее желчной кислоты
KR102051031B1 (ko)	2011-10-28	2019-12-02	루메나 파마수티컬즈, 인코포레이티드	고담혈증 및 담즙 정체성 간 질환 치료용 담즙산 재순환 억제제
BR112014010223B8 (pt)	2011-10-28	2021-02-23	Lumena Pharmaceuticals Llc	uso de uma composição compreendendo inibidores de reciclagem de ácido de bílis e forma de dosagem pediátrica
KR20160003664A (ko)	2013-03-15	2016-01-11	루메나 파마수티컬즈, 인코포레이티드	바렛 식도 및 위식도 역류 질환 치료용 담즙산 재순환 억제제
EP2968230A2 (en)	2013-03-15	2016-01-20	Lumena Pharmaceuticals, Inc.	Bile acid recycling inhibitors for treatment of primary sclerosing cholangitis and inflammatory bowel disease
JO3301B1 (ar)	2013-04-26	2018-09-16	Albireo Ab	تعديلات بلورية على إيلوبيكسيبات
CN106659726A (zh)	2014-06-25	2017-05-10	Ea制药株式会社	固体制剂及其着色防止或着色减少方法
EP3012252A1 (en)	2014-10-24	2016-04-27	Ferring BV	Crystal modifications of elobixibat
EP3413878B1 (en)	2016-02-09	2021-04-14	Albireo AB	Oral cholestyramine formulation and use thereof
EP3413875B1 (en)	2016-02-09	2020-01-29	Albireo AB	Cholestyramine pellets and methods for preparation thereof
EP3413877B1 (en)	2016-02-09	2021-04-07	Albireo AB	Oral cholestyramine formulation and use thereof
JP2020530448A (ja)	2017-08-09	2020-10-22	アルビレオ・アクチボラグ	コレスチラミン顆粒、経口コレスチラミン製剤、及びそれらの使用
CN110996915B (zh)	2017-08-09	2023-10-03	阿尔比里奥公司	考来烯胺丸粒、口服考来烯胺制剂及其用途
JP7391048B2 (ja)	2018-06-05	2023-12-04	アルビレオ・アクチボラグ	ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
MX2020013839A (es)	2018-06-20	2021-03-25	Albireo Ab	Formulacion farmaceutica de odevixibat.
US11801226B2 (en)	2018-06-20	2023-10-31	Albireo Ab	Pharmaceutical formulation of odevixibat
US11007142B2 (en)	2018-08-09	2021-05-18	Albireo Ab	Oral cholestyramine formulation and use thereof
US11549878B2 (en)	2018-08-09	2023-01-10	Albireo Ab	In vitro method for determining the adsorbing capacity of an insoluble adsorbant
US10722457B2 (en)	2018-08-09	2020-07-28	Albireo Ab	Oral cholestyramine formulation and use thereof
RS63899B1 (sr)	2019-02-06	2023-02-28	Albireo Ab	Benzotiadiazepinska jedinjenja i njihova upotreba kao modulatora žučnih kiselina
TWI835997B (zh)	2019-02-06	2024-03-21	瑞典商艾爾比瑞歐公司	苯并噻氮呯化合物及其用作膽酸調節劑之用途
CA3129826A1 (en)	2019-02-12	2020-08-20	Mirum Pharmaceuticals, Inc.	Methods for treating cholestasis
BR112022010505A2 (pt)	2019-12-04	2022-09-06	Albireo Ab	Compostos de benzotia(di)azepina e seu uso como moduladores do ácido biliar
US11014898B1 (en)	2020-12-04	2021-05-25	Albireo Ab	Benzothiazepine compounds and their use as bile acid modulators
AR120682A1 (es)	2019-12-04	2022-03-09	Albireo Ab	Compuestos de benzotiadiazepina y su uso como moduladores del ácido biliar
EP4069359B1 (en)	2019-12-04	2024-01-03	Albireo AB	Benzothia(di)azepine compounds and their use as bile acid modulators
JP7665620B2 (ja)	2019-12-04	2025-04-21	アルビレオ・アクチボラグ	ベンゾチアジアゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
TWI867107B (zh)	2019-12-04	2024-12-21	瑞典商艾爾比瑞歐公司	苯并噻(二)氮呯化合物及其作為膽酸調節劑之用途
WO2021110887A1 (en)	2019-12-04	2021-06-10	Albireo Ab	Benzothiazepine compounds and their use as bile acid modulators
WO2021110886A1 (en)	2019-12-04	2021-06-10	Albireo Ab	Benzothia(di)azepine compounds and their use as bile acid modulators
CA3158181A1 (en)	2019-12-04	2021-06-10	Albireo Ab	Benzothia(di)azepine compounds and their use as bile acid modulators
AR120679A1 (es)	2019-12-04	2022-03-09	Albireo Ab	Compuestos de benzoti(di)azepina y su uso como moduladores ácido biliar
WO2022029101A1 (en)	2020-08-03	2022-02-10	Albireo Ab	Benzothia(di)azepine compounds and their use as bile acid modulators
CA3186857A1 (en)	2020-08-03	2022-02-10	Per-Goran Gillberg	Benzothia(di)azepine compounds and their use as bile acid modulators
AU2021379076A1 (en)	2020-11-12	2023-06-08	Albireo Ab	Odevixibat for treating progressive familial intrahepatic cholestasis (pfic)
AU2021390172A1 (en)	2020-12-04	2023-06-22	Albireo Ab	Benzothia(di)azepine compounds and their use as bile acid modulators
TW202313579A (zh)	2021-06-03	2023-04-01	瑞典商艾爾比瑞歐公司	苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途
CN119343140A (zh)	2022-06-09	2025-01-21	阿尔比里奥公司	治疗肝炎
JP2025521736A (ja)	2022-07-05	2025-07-10	アルビレオ・アクチボラグ	ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
CN120265290A (zh)	2022-12-09	2025-07-04	阿尔比里奥公司	治疗肾脏疾病的asbt抑制剂
WO2025146507A1 (en)	2024-01-05	2025-07-10	Albireo Ab	Benzothia(di)azepine compounds and their use as bile acid modulators
WO2025146508A1 (en)	2024-01-05	2025-07-10	Albireo Ab	Benzothia(di)azepine compounds and their use as bile acid modulators

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5994391A (en) *	1994-09-13	1999-11-30	G.D. Searle And Company	Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
BR9508916A (pt) *	1994-09-13	1997-12-30	Monsanto Co	"Novas benzotiepinas tendo atividade como inibidores de transporte do ácido biliar ileal e absorção de taurocolato"
NZ331813A (en) *	1996-03-11	2001-03-30	G	Benzothiepine compounds having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US6221897B1 (en) *	1998-06-10	2001-04-24	Aventis Pharma Deutschland Gmbh	Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
AU5301599A (en) *	1998-08-20	2000-03-14	Takeda Chemical Industries Ltd.	Quaternary ammonium salts and their use

1998
- 1998-06-10 DE DE19825804A patent/DE19825804C2/de not_active Expired - Lifetime
1999
- 1999-05-28 AT AT99927784T patent/ATE227715T1/de active
- 1999-05-28 TR TR2000/03634T patent/TR200003634T2/xx unknown
- 1999-05-28 CZ CZ20004592A patent/CZ297989B6/cs not_active IP Right Cessation
- 1999-05-28 KR KR1020007013964A patent/KR100681721B1/ko not_active Expired - Fee Related
- 1999-05-28 HU HU0102256 patent/HU229761B1/hu not_active IP Right Cessation
- 1999-05-28 AU AU45019/99A patent/AU753275B2/en not_active Ceased
- 1999-05-28 CA CA002334775A patent/CA2334775C/en not_active Expired - Fee Related
- 1999-05-28 ID IDW20002562A patent/ID28695A/id unknown
- 1999-05-28 PL PL344827A patent/PL196074B1/pl unknown
- 1999-05-28 EP EP99927784A patent/EP1086092B1/de not_active Expired - Lifetime
- 1999-05-28 DE DE59903411T patent/DE59903411D1/de not_active Expired - Lifetime
- 1999-05-28 DK DK99927784T patent/DK1086092T3/da active
- 1999-05-28 US US09/719,047 patent/US6387944B1/en not_active Expired - Lifetime
- 1999-05-28 BR BRPI9912188-3A patent/BR9912188B1/pt not_active IP Right Cessation
- 1999-05-28 JP JP2000553419A patent/JP4374426B2/ja not_active Expired - Fee Related
- 1999-05-28 CN CN99807171A patent/CN1127497C/zh not_active Expired - Fee Related
- 1999-05-28 RU RU2001101491/04A patent/RU2215001C2/ru not_active IP Right Cessation
- 1999-05-28 PT PT99927784T patent/PT1086092E/pt unknown
- 1999-05-28 ES ES99927784T patent/ES2182535T3/es not_active Expired - Lifetime
- 1999-05-28 WO PCT/EP1999/003701 patent/WO1999064410A1/de not_active Ceased
- 1999-05-29 PT PT99927802T patent/PT1086113E/pt unknown
- 1999-05-29 TR TR2000/03632T patent/TR200003632T2/xx unknown
- 1999-05-29 EP EP99927802A patent/EP1086113B1/de not_active Expired - Lifetime
- 1999-05-29 AT AT99927802T patent/ATE259372T1/de active
- 1999-05-29 CA CA002334773A patent/CA2334773C/en not_active Expired - Lifetime
- 1999-05-29 PL PL99345901A patent/PL196057B1/pl unknown
- 1999-05-29 WO PCT/EP1999/003743 patent/WO1999064409A2/de not_active Ceased
- 1999-05-29 DE DE59908522T patent/DE59908522D1/de not_active Expired - Lifetime
- 1999-05-29 ID IDW20002564A patent/ID26876A/id unknown
- 1999-05-29 IL IL14007899A patent/IL140078A/en not_active IP Right Cessation
- 1999-05-29 JP JP2000553418A patent/JP3374129B2/ja not_active Expired - Lifetime
- 1999-05-29 AU AU45031/99A patent/AU752633B2/en not_active Expired
- 1999-05-29 KR KR1020007013931A patent/KR100562184B1/ko not_active Expired - Lifetime
- 1999-05-29 BR BRPI9911123-3A patent/BR9911123B1/pt not_active IP Right Cessation
- 1999-05-29 ES ES99927802T patent/ES2215387T3/es not_active Expired - Lifetime
- 1999-05-29 RU RU2001101499/04A patent/RU2220141C2/ru active
- 1999-05-29 HU HU0102554A patent/HU228570B1/hu unknown
- 1999-05-29 DK DK99927802T patent/DK1086113T3/da active
- 1999-05-29 CZ CZ20004591A patent/CZ297925B6/cs not_active IP Right Cessation
- 1999-05-29 NZ NZ508681A patent/NZ508681A/en not_active IP Right Cessation
- 1999-05-29 CN CNB998071722A patent/CN1152039C/zh not_active Expired - Lifetime
- 1999-06-08 AR ARP990102715A patent/AR018633A1/es active IP Right Grant
- 1999-06-08 AR ARP990102716A patent/AR018634A1/es active IP Right Grant
2000
- 2000-11-30 ZA ZA200007061A patent/ZA200007061B/en unknown
- 2000-11-30 ZA ZA200007060A patent/ZA200007060B/xx unknown
- 2000-12-08 NO NO20006251A patent/NO327075B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
WO1999064410A1 (de)	1999-12-16
NO20006251L (no)	2001-02-07
KR100562184B1 (ko)	2006-03-20
PL345901A1 (en)	2002-01-14
HUP0102554A3 (en)	2002-12-28
ZA200007060B (en)	2001-07-18
NO20006251D0 (no)	2000-12-08
CA2334773A1 (en)	1999-12-16
HK1036799A1 (en)	2002-01-18
NO327075B1 (no)	2009-04-20
JP3374129B2 (ja)	2003-02-04
EP1086113A2 (de)	2001-03-28
PT1086113E (pt)	2004-06-30
WO1999064409A3 (de)	2000-03-02
HUP0102256A3 (en)	2002-04-29
DE19825804C2 (de)	2000-08-24
RU2215001C2 (ru)	2003-10-27
AU4501999A (en)	1999-12-30
IL140078A0 (en)	2002-02-10
BR9911123B1 (pt)	2010-12-14
PL196074B1 (pl)	2007-12-31
BR9911123A (pt)	2006-01-03
HU228570B1 (en)	2013-04-29
DK1086092T3 (da)	2003-03-10
ES2215387T3 (es)	2004-10-01
DK1086113T3 (da)	2004-05-24
CZ20004591A3 (cs)	2001-04-11
CA2334773C (en)	2009-05-26
HK1039490A1 (en)	2002-04-26
PL196057B1 (pl)	2007-11-30
PL344827A1 (en)	2001-11-19
KR20010052701A (ko)	2001-06-25
HU229761B1 (hu)	2014-06-30
BR9912188A (pt)	2001-04-10
AR018634A1 (es)	2001-11-28
JP2002517491A (ja)	2002-06-18
CZ20004592A3 (cs)	2001-04-11
CA2334775C (en)	2009-10-13
TR200003632T2 (tr)	2001-04-20
CA2334775A1 (en)	1999-12-16
CN1152039C (zh)	2004-06-02
KR100681721B1 (ko)	2007-02-15
DE59908522D1 (de)	2004-03-18
EP1086092B1 (de)	2002-11-13
HUP0102256A1 (hu)	2001-12-28
CZ297989B6 (cs)	2007-05-16
DE59903411D1 (de)	2002-12-19
EP1086092A1 (de)	2001-03-28
DE19825804A1 (de)	1999-12-16
BR9912188B1 (pt)	2010-12-14
ZA200007061B (en)	2001-07-18
CN1305469A (zh)	2001-07-25
HUP0102554A1 (hu)	2001-10-28
CN1305487A (zh)	2001-07-25
AU4503199A (en)	1999-12-30
EP1086113B1 (de)	2004-02-11
ID26876A (id)	2001-02-15
US6387944B1 (en)	2002-05-14
ATE227715T1 (de)	2002-11-15
NZ508681A (en)	2002-06-28
TR200003634T2 (tr)	2001-06-21
RU2220141C2 (ru)	2003-12-27
ID28695A (id)	2001-06-28
CZ297925B6 (cs)	2007-05-02
PT1086092E (pt)	2003-03-31
AR018633A1 (es)	2001-11-28
KR20010052682A (ko)	2001-06-25
WO1999064409A2 (de)	1999-12-16
CN1127497C (zh)	2003-11-12
ATE259372T1 (de)	2004-02-15
JP2002517490A (ja)	2002-06-18
AU753275B2 (en)	2002-10-10
ES2182535T3 (es)	2003-03-01
JP4374426B2 (ja)	2009-12-02
AU752633B2 (en)	2002-09-26

Legal Events

Date	Code	Title
2005-01-24	FF	Patent granted
2005-03-20	KB	Patent renewed
2009-12-24	KB	Patent renewed
2013-05-30	KB	Patent renewed
2017-06-29	KB	Patent renewed
2019-12-31	EXP	Patent expired

Publication	Publication Date	Title
CA2334773C (en)	2009-05-26	Benzothiepine-1,1-dioxide derivatives, method for producing them, medicaments containing these compounds and their use
US6642269B2 (en)	2003-11-04	Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
AU765199B2 (en)	2003-09-11	1,4-benzothiazepine-1,1-dioxide derivatives substituted by sugar radicals, methods for the production thereof, medicaments containing these compounds and the use thereof
MXPA00012207A (en)	2001-12-13	Benzothiepine-1,1-dioxide derivatives, method for producing them, medicaments containing these compounds and their use
MXPA01009941A (en)	2002-05-09	1,4-benzothiazepine-1,1-dioxide derivatives substituted by sugar radicals, methods for the production thereof, medicaments containing these compounds and the use thereof
HK1039490B (en)	2004-12-10	Benzothiepine-1, 1-dioxide derivatives, method for producing them, composition containing these compounds and their use
MXPA00012208A (en)	2001-12-13	BENZO(b)THIEPINE-1,1-DIOXIDE DERIVATIVES, A METHOD FOR THE PRODUCTION THEREOF, MEDICAMENTS CONTAINING THESE COMPOUNDS, AND THEIR USE
CZ322899A3 (cs)	2000-08-16	Kombinovaná terapie využívající ileální transport žlučových kyselin inhibovaný benzothiepiny HMG Co-A reduktázovými inhibitory